Recent Company News

• 04:30 PM ET Mar 19, 2026
  

  Teva Releases Q1 2026 Aide Memoire

• 04:30 PM ET Mar 19, 2026
  

  Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

• 01:44 AM ET Mar 19, 2026
  

  Formycon announces settlement and licensing agreement for FYB203 concluded with Regeneron and Bayer; all pending patent litigations fully resolved (€19.82, 0.00)

• 11:54 AM ET Mar 16, 2026
  

  StreetAccount Summary - U.S. Unusual Option Volume: VIX (11.7%) to $24.00; S&P 500 +1.2% to $6,714.40

• 08:39 AM ET Mar 10, 2026
  

  Transcript Intelligence: Teva Pharmaceutical at Barclays Global Healthcare Conference ($31.50, 0.00)

• 11:17 AM ET Mar 09, 2026
  

  FDA takes additional steps to streamline development of biosimilar medicines and make them more affordable

• 10:23 AM ET Mar 09, 2026
  

  Transcript Intelligence: Teva Pharmaceutical at Leerink Global Healthcare Conference ($30.07, -0.98)

• 05:46 PM ET Mar 04, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:17 AM ET Mar 04, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:37 AM ET Mar 04, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market